| 10 December 2018

USH2018 Patient Symposium - videos & transcripts now available


The International Symposium on Usher Syndrome held in Mainz on July 19-21, 2018 was a great success. An unprecedented number attendees from all over the world were present. More than 250 people from around the world attended the multi-day gathering in-person, and more than 150 joined the Patient Symposium via livestream, making it the single largest event ever held for the Usher syndrome community.

| 28 November 2018

'Retina Bulgaria' website launched


Retina International congratulates our newest member Retina Bulgaria on the launch of their new website https://retinabulgaria.bg/bg . This website brings information about retinal conditions and treatments to Bulgarian patients in their own language. It also creates awareness of the educational tools provided by Retina International's Toolkits for patients worldwide, by linking patients with RI's sites.


| 26 October 2018

International Search - ICO Chief Executive Officer

The International Council of Ophthalmology (ICO) is conducting an international search to fill a vacancy for the position of Chief Executive Officer (CEO) and is now accepting applications.


| 11 October 2018

World Sight Day 2018 - #EyeCareEverywhere


On October 11th 2018, we celebrate World Sight Day, an annual day of awareness held on the second Thursday of October to focus global attention on blindness and vision impairment. The theme of World Sight Day 2018 (WSD2018) is Universal Eye Health and this year's ‘Call to Action’ is EYE CARE EVERYWHERE.


| 11 October 2018

Genetic testing for IRDs varies widely across the RI membership

In order to understand the current status of the genetic testing pathway for IRD patients, we asked our members what the experiences are in their countries. Nine respondents from both EU and non-EU countries revealed disparities in test type availability, access and payment options. (Italy, Austria, Poland, Germany (two replies), Ireland, Iceland, Brazil, South Africa).

| 24 September 2018

Luxturna, the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene, recommended for approval by the European Medicines Agency


Inherited retinal diseases are forms of blindness where vision problems appear in children or young adults and can progress to total loss of sight. They are a collection of diseases that can be caused by one of over 200 known genes. The mutations of the RPE65 gene, which encodes one of the enzymes involved in the biochemistry of light capture by the cells of the retina, hinder the patient’s ability to detect light. It is a severely debilitating disease, characterised by a progressive loss of vision. Most patients will be blind by the time they are young adults.

Join Our Mailing List